Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.35 |
| ▸ | ATP4A | P20648 | 1/20 | 0.35 |
| ▸ | ATP4B | P51164 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587688 | 0.98 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP19A1ATP4A | |
| SCHEMBL10192245 | 0.94 | ATP4A (0.39) | SLC6A2SLC6A4SLC6A3CYP19A1ATP4A | |
| SCHEMBL12811511 | 0.86 | — | — | |
| SCHEMBL14578735 | 0.83 | CYP19A1 (0.35) | CYP19A1HTR4DPP4FOLH1ALDH1A1 | |
| SCHEMBL13201562 | 0.78 | ATP4A (0.53) | CYP19A1ATP4AATP4B | |
| SCHEMBL628307 | 0.78 | TBXAS1 (0.42) | CYP19A1DPP4ALDH1A1 | |
| SCHEMBL7265318 | 0.77 | CYP19A1 (0.38) | CYP19A1FOLH1 | |
| SCHEMBL14189706 | 0.77 | ATP4A (0.52) | CYP19A1ATP4AATP4B | |
| SCHEMBL20204363 | 0.76 | TBXAS1 (0.46) | CYP19A1 | |
| SCHEMBL11204798 | 0.76 | TBXAS1 (0.46) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | SLC6A2 1883/4885SLC6A4 2840/4885SLC6A3 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.